Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03496168 · ClinicalTrials.gov registry record · Phase 2
Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT03496168 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 13 participants.
The verdict
NCT03496168, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a multicenter open-label study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM) who previously participated in study MYK-461-004 (PIONEER-HCM).
Interventions
- DRUG mavacamten
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-04-26 |
| Est. Completion | 2023-11-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03496168
The ClinicalTrials.gov registry entry for NCT03496168 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mavacamten is the first listed.
NCT03496168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03496168 about?
NCT03496168 is a clinical study titled "Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER". This is a multicenter open-label study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM) who previously participated in study MYK-461-004 (PIONEER-HCM).
What is the current status of trial NCT03496168?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2018-04-26. Estimated completion is 2023-11-09.
What interventions are being tested in trial NCT03496168?
The interventions under investigation include: mavacamten (DRUG).
Who is sponsoring clinical trial NCT03496168?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.